US$ 20.93
glp 1 approval Figure 2, Health Canada Timeline for GLP-1 Receptor Agonists by Marketed Date and NOC Dates - Formulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Visible Alpha GLP-1 drug monitor
Description
Karasik A., Charbonnel B., Liu J., Wu M., Meehan A., and Meininger G., Sitagliptin Added to Ongoing Metformin Therapy Enhanced Glycemic Control and BetaCell Function in Patients With Type 2 Diabetes, Diabetes 55, no
The gastrointestinal effects result primarily from delayed gastric emptying and altered gut motility

Here is the critical part: aim the needle at the glass wall of the vial, not directly at the powder

doi:10.3390/medicina61111987 4

If symptoms persist beyond 8 weeks at a stable dose, clinical evaluation is important to exclude other causes (infection, dietary intolerance, concurrent medications)
